Adheris Health (AHE) investor relations material

Executive summary

• Q1 FY27 revenue, gross profit and gross margin rose YoY and materially QoQ, supported by out-of-cycle bookings, customer win-backs and program expansions.

• CY27 pipeline momentum strengthened, with close to 110 opportunities across 40+ clients and almost 90 brands as of 23 October 2026.

Financial highlights

• Revenue was $6.4m, up 1.6% YoY and 60.5% QoQ; gross profit was $2.9m, up 8.4% YoY and 104.6% QoQ.

• Net operating cash outflow was $3.1m, in line with expectations; operating cash receipts were $3.2m versus $7.6m in Q1 FY26.

• Staff costs excluding contractors and consultants were $2.2m; administration and corporate costs were $0.4m, both lower YoY.

Outlook and guidance

• More than half of CY27 pipeline value is in higher-margin THRiV and digital engagement programs; seven-figure programs represent about half of pipeline value.

• The CY27 pipeline is larger and more diversified than the FY26 booking base; no single program or brand exceeds 10% of pipeline value.

• A pharmacy partner's exit from sponsored programs from 1 January 2027 reduces patient reach but is not expected to affect FY27 budgeted revenue.

• The quarter's higher-than-normal operating cash outflows reflected payment timing and are not expected to recur; additional funding is not currently anticipated.